Literature DB >> 9615744

Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids.

S Toma1, L Isnardi, L Riccardi, W Bollag.   

Abstract

Induction of apoptosis in MCF-7 breast carcinoma cell line by various retinoids was measured by cytofluorimetry and DNA fragmentation assay. Retinoids with marked or high selectivity for RAR alpha, RAR beta, RAR gamma or RXR alpha were tested. All these retinoids were capable of inducing apoptosis, in a dose- and time-dependent way. MCF-7 cell line expressed RAR alpha, RAR gamma and RXRs, but not RAR beta. Compared to untreated MCF-7 cells, after 2 days of incubation with each of the selective retinoids, a substantial increase in apoptotic cells was observed, even at the lowest concentration of 10(-8) M. Among the various analysed selective retinoids only slight differences were observed. All-trans retinoic acid and 13-cis retinoic acid induced apoptosis only after 6 days and 9-cis-retinoic acid after 4 days of incubation. Since all receptor selective retinoids substantially inducedapoptosis, it may be concluded that RAR alpha, RAR gamma and RXR alpha are able to mediate programmed cell death in the tested tumor cell line. Highly selective retinoid receptor agonists and antagonists may be useful for clarifying the function of retinoid receptors and for further progress in the field of cancer prevention and therapy by retinoids.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9615744

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Role of retinoid receptors in the prevention and treatment of breast cancer.

Authors:  L M Yang; C Tin-U; K Wu; P Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  Mouse retinol binding protein gene: cloning, expression and regulation by retinoic acid.

Authors:  K A Jessen; M A Satre
Journal:  Mol Cell Biochem       Date:  2000-08       Impact factor: 3.396

3.  Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).

Authors:  M M Webber; D Bello-DeOcampo; S Quader; N D Deocampo; W S Metcalfe; R M Sharp
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

Review 4.  Antiestrogens--tamoxifen, SERMs and beyond.

Authors:  K Dhingra
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells.

Authors:  Eun-Jung Park; Tamara P Kondratyuk; Andrew Morrell; Evgeny Kiselev; Martin Conda-Sheridan; Mark Cushman; Soyoun Ahn; Yongsoo Choi; Jerry J White; Richard B van Breemen; John M Pezzuto
Journal:  Cancer Prev Res (Phila)       Date:  2011-04

Review 6.  Toward checkmate: biology and breast cancer therapy for the new millennium.

Authors:  K D Miller; G W Sledge
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

7.  Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors.

Authors:  Thaddeus T Schug; Daniel C Berry; Natacha S Shaw; Skylar N Travis; Noa Noy
Journal:  Cell       Date:  2007-05-18       Impact factor: 41.582

8.  Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.

Authors:  N Ariga; T Moriya; T Suzuki; M Kimura; N Ohuchi; H Sasano
Journal:  Jpn J Cancer Res       Date:  2000-11

9.  Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.

Authors:  Ana M Jiménez-Lara; Ana Aranda; Hinrich Gronemeyer
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

Review 10.  Cooperating transcription factors mediate the function of estrogen receptor.

Authors:  Elisa Fiorito; Madhumohan R Katika; Antoni Hurtado
Journal:  Chromosoma       Date:  2012-11-29       Impact factor: 4.316

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.